**Supplementary Table 1. Parameters of one-way sensitivity analysis.**

|  |  |  |  |
| --- | --- | --- | --- |
| Input | MIN | MAX | Source |
| Waning rate | 0% | 10% | Assumption |
| Discount rates (costs) | 0% | 5% | Assumption |
| Discount rates (utilities) | 0% | 5% | Assumption |
| Vaccine efficacy duration | 7,5 years (HZ), 5 years (PHN) | 20 years | Assumption |
| Vaccine efficacy HZ  (age cohort split)  60-69  70-79 | Lower limit of 95%  56%  28% | Upper limit of 95%  71%  52% | [5] |
| Vaccine efficacy PHN  (age cohort split)  60-69  70-79 | Lower limit of 95%  20.4%  43.3% | Upper limit of 95%  86.7%  81.3% | [5] |
| Utilities HZ (pain split)  No pain  Mild pain  Moderate pain  Severe pain | 0.86  0.73  0.60  0.47 | 0.86  0.77  0.68  0.55 | Min [20]  Max [23] |
| Utilities PHN (pain split)  Mild pain  Moderate pain  Severe pain | 0.73  0.60  0.47 | 0.77  0.68  0.55 | Min [20]  Max [23] |
| HZ Incidence | 0.0351% | 0.0720% | [4] |
| PHN Incidence | 14.30% | 24.50% | [17] |
| Vaccine price | € 80 | € 120 | Assumption |
| Total costs | 20% decrease | 20% increase | Assumption |
| Method for utilities | Additive | Multiplicative | [9] |